Figure 6.

sEVs-Upregulated FOXP3 Is Dependent on the ATM-AMPK-SIRT1/SIRT2/SIRT6 Axis

(A) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 50 μM KU60019, BxPC-3-derived sEVs, and sEVs combined with 50 μM KU60019, respectively.

(B) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 20 μM Compound C, BxPC-3-derived sEVs, and sEVs combined with 20 μM Compound C, respectively.

(C) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 10 μM EX-527, BxPC-3-derived sEVs, and sEVs combined with 10 μM EX-527, respectively.

(D) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 40 μM AGK2, BxPC-3-derived sEVs, and sEVs combined with 40 μM AGK2, respectively.

(E) Peripheral T lymphocytes derived from three healthy humans were treated with DMSO, 100 μM OSS_128167, BxPC-3-derived sEVs, and sEVs combined with 100 μM OSS_128167, respectively.

(F) T lymphocytes were from the same source as (A–E). Flow cytometry showing the FOXP3 expression.

(A–F) Data shown are mean ± standard deviation. n = 3. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; NS, no significant difference (two-tailed, unpaired Student's t test).

Graphs of western blots and flow cytometry are from a single experiment, which is representative of three independent experiments.